Last updated: October 7, 2024
Sponsor: University of Kansas Medical Center
Overall Status: Completed
Phase
N/A
Condition
Scar Tissue
Cystic Fibrosis
Lung Disease
Treatment
exercise
Clinical Study ID
NCT04543929
STUDY00143513
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
diagnosed with Cystic Fibrosis
Prescribed and taking for 28 days ivacaftor-tezacaftor-elexacaftor (Trikafta)
18 years and older
Exclusion
Exclusion Criteria:
17 years of age or less
not eligible for ivacaftor-tezacaftor-elexacaftor (Trikafta)
inability to exercise
pregnancy
status post lung transplantation
already participating in more than 150 minutes of aerobic exercise per week
Study Design
Total Participants: 9
Treatment Group(s): 1
Primary Treatment: exercise
Phase:
Study Start date:
February 11, 2020
Estimated Completion Date:
June 23, 2020
Study Description
Connect with a study center
University of Kansas Medical Center
Kansas City, Kansas 66160
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.